Neuroimmunology Reports最新文献_第9页

Decades-delayed onset of subcutaneous granulomata and calcifications from interferon-beta-1a in a patient with multiple sclerosis 多发性硬化症患者皮下肉芽肿和钙化的干扰素- β -1a延迟发作数十年

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-11-17 DOI: 10.1016/j.nerep.2023.100190

Mara Bahri , Kristi Epstein , Yinan Zhang

引用次数: 0

Treatment of recurrent VZV myelitis with intravenous immunoglobulin 静脉注射免疫球蛋白治疗复发性VZV脊髓炎

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-08-29 DOI: 10.1016/j.nerep.2023.100181

Danelvis Paredes, Elijah Lackey, Christopher Eckstein

{"title":"Treatment of recurrent VZV myelitis with intravenous immunoglobulin","authors":"Danelvis Paredes, Elijah Lackey, Christopher Eckstein","doi":"10.1016/j.nerep.2023.100181","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100181","url":null,"abstract":"<div><h3>Background</h3><p>VZV myelitis is a rare and typically monophasic complication of VZV reactivation. There is no solid evidence for a particular treatment regimen for VZV myelitis, especially in recurrent disease. No prior reports or studies have looked at using intravenous immunoglobulin for this condition, particularly for refractory cases.</p></div><div><h3>Case report</h3><p>A 75-year-old female presented with paresthesia on the right lateral leg, followed by a vesicular rash in a T2 dermatomal distribution. Over a period of 2 weeks, she experienced bilateral lower extremity weakness. MRI revealed a C3-C6 enhancing lesion. VZV positivity was confirmed by skin biopsy. She was treated with 5 days of Solumedrol 1gm IV and valacyclovir 1gm TID with improvement of weakness and rash. However, over the next two years, she continued to get occasional disseminated vesicular rash with each flare of her myelitis despite continued valacyclovir. She was started on monthly IV Ig (1gm/kg IV Ig over 2 days) for her recurrent myelitis. Since starting monthly IV Ig there have been no further zoster outbreaks or episodes of myelitis. Her balance and gait have improved significantly.</p></div><div><h3>Conclusion</h3><p>We present an unusual case of recurrent disseminated zoster with myelitis successfully treated with monthly IV Ig. The successful treatment of this patient should prompt consideration for its use in similar cases of recurrent VZV myelitis and may provide insight for future studies on how to treat VZV-related diseases.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100181"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50193894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diaphragmatic pacing for neurogenic respiratory failure in neuromyelitis optica spectrum disorder: A case series 膈肌起搏治疗视神经脊髓炎谱系障碍的神经源性呼吸衰竭：一系列病例

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-09-03 DOI: 10.1016/j.nerep.2023.100184

Hannah Kelly , Hesham Abboud , Alessandro Serra , Mary Jo Elmo , Raymond Onders

引用次数: 0

Anti-N-methyl-d-aspartate receptor encephalitis in a patient on long-term continuous immunomodulatory therapy 一例长期持续免疫调节治疗的抗N-甲基-d-天冬氨酸受体脑炎患者

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-08-28 DOI: 10.1016/j.nerep.2023.100182

Lina M. Ariza-Serrano , Nicole Andrea Gómez Perdomo , Antonio Schlesinger , Manuel Tapias , Steven Hurtado

{"title":"Anti-N-methyl-d-aspartate receptor encephalitis in a patient on long-term continuous immunomodulatory therapy","authors":"Lina M. Ariza-Serrano , Nicole Andrea Gómez Perdomo , Antonio Schlesinger , Manuel Tapias , Steven Hurtado","doi":"10.1016/j.nerep.2023.100182","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100182","url":null,"abstract":"<div><h3>Background</h3><p>Anti-N-methyl-<span>d</span>-aspartate [anti-NMDA] receptor encephalitis is one of the most common types of immune-mediated encephalitis. It is characterized by a neuropsychiatric syndrome associated with immunoglobulin G [IgG]-type antibodies against the NMDA receptor's GluN1 subunit in cerebrospinal fluid [CSF]. To our Knowledge, only six cases of autoimmune encephalitis with positive CSF NMDA receptor IgG autoantibodies have been reported among patients on long-term immunosuppressive therapies. The etiologies of all six cases were related to solid organ transplantation. Therefore, this report is the first to present a case of immunosuppression associated with an etiology other than post-transplant immunosuppression.</p></div><div><h3>Case presentation</h3><p>We present the case of a 59-year-old female patient who was on a long-term continuous immunomodulatory therapy for rheumatoid arthritis, and she consulted the emergency department several times for headache, symptoms of neurologic deficit, and subsequent progression to neuropsychiatric symptoms. CSF examination of the patient confirmed the presence of antibodies against the NMDA receptor; hence, the diagnosis of anti-NMDA receptor encephalitis was made.</p></div><div><h3>Conclusions</h3><p>It is important to recognize the clinical features of autoimmune encephalitis and to consider this condition in the differential diagnosis when neuropsychiatric symptoms are manifested in such patients. Patients on long-term immunomodulatory therapy present with atypical manifestations of anti-NMDA receptor encephalitis. The consideration of these manifestations in the differential diagnosis can ensure efficient diagnosis, management, and reduction in the consequences affecting morbidity and mortality of these patients.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100182"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50193887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumefactive demyelinating lesion due to neuromyelitis optica spectrum disorder: Successful relapse prevention with eculizumab 视神经脊髓炎谱系障碍引起的肿瘤性脱髓鞘病变：埃库珠单抗成功预防复发

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-09-17 DOI: 10.1016/j.nerep.2023.100188

Kimberly A. O'Neill , Ukuemi Edema , Lauren Gluck

引用次数: 0

CADASIL progression after neurologic infectious insults: Case report of a new pathogenic NOTCH3 mutation 神经系统感染性损伤后CADASIL进展：一例新的致病性NOTCH3突变病例报告

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-09-17 DOI: 10.1016/j.nerep.2023.100186

Kelli M. Money , Jamie Cronin , Amy Guimaraes-Young , Aaron Carlson , Mark A. Lovell , Elizabeth Matthews , Karen D. Orjuela , Daniel M. Pastula , Eric P. Wartchow , Amanda L. Piquet

{"title":"CADASIL progression after neurologic infectious insults: Case report of a new pathogenic NOTCH3 mutation","authors":"Kelli M. Money , Jamie Cronin , Amy Guimaraes-Young , Aaron Carlson , Mark A. Lovell , Elizabeth Matthews , Karen D. Orjuela , Daniel M. Pastula , Eric P. Wartchow , Amanda L. Piquet","doi":"10.1016/j.nerep.2023.100186","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100186","url":null,"abstract":"<div><h3>Background</h3><p>Cerebral autosomal dominant arteriopathy with subcortical infarcts (CADASIL) is the most common monogenic inherited small vessel disease. Autoimmune disorders, including multiple sclerosis, have been documented to co-exist with CADASIL, which can complicate the initial recognition. Inflammatory insults have been suggested to be associated with disease progression with SARS-CoV-2 infection.</p></div><div><h3>Case Report</h3><p>We present a case of a white woman in her 50 s who demonstrated progressive white matter changes with initial demyelinating characteristics in 2010. Their course was notable for accelerated progression after multiple central nervous system insults, including herpes simplex virus (HSV) encephalitis in 2017, suspected post-infectious autoimmune encephalitis in 2018, and neuroinvasive West Nile virus (WNV) infection with confirmed para-infectious NMDA receptor encephalitis in 2022. CADASIL was suspected given confluent anterior temporal and external capsule white matter changes. She was found to have a novel <em>NOTCH3</em> missense mutation in exon 3 (c.313T>C, p.(Ser105Pro)), and electron microscopy of a skin biopsy demonstrated granular osmiophilic material deposits diagnostic of CADASIL.</p></div><div><h3>Conclusion</h3><p>This case demonstrates a novel pathogenic <em>NOTCH3</em> mutation as well as the complexity of CADASIL diagnosis in the setting of possible concomitant demyelinating disease and other central nervous system insults. Significant phenotypic variability and overlapping acquired pathologies can make CADASIL recognition difficult. Given precipitous decline with each central nervous system insult in this case, we suspect these events hastened CADASIL progression.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100186"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50193891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of refractory tumefactive multiple sclerosis in an African American woman 非裔美国妇女难治性肿瘤性多发性硬化症1例

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-11-15 DOI: 10.1016/j.nerep.2023.100192

Conor Kelly , Jennings Gyedu , Rock Heyman , Cigdem Isitan Alkawadri

{"title":"A case of refractory tumefactive multiple sclerosis in an African American woman","authors":"Conor Kelly , Jennings Gyedu , Rock Heyman , Cigdem Isitan Alkawadri","doi":"10.1016/j.nerep.2023.100192","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100192","url":null,"abstract":"<div><h3>Background</h3><p>Tumefactive multiple sclerosis (TMS) is a rare subtype of multiple sclerosis (MS) that poses a diagnostic and therapeutic challenge, with relatively little available published data. Though studies have demonstrated similar disease course in TMS with non-tumefactive disease, refractory cases requiring early escalation of therapy are noted and risk factors are unclear. Furthermore, no studies have presented data specifically on adult African American patients with TMS.</p></div><div><h3>Case report</h3><p>We present a case of TMS refractory to steroids and plasma exchange in an African-American woman. Disease progression was halted after treatment with cyclophosphamide. The patient was later transitioned to rituximab maintenance therapy.</p></div><div><h3>Conclusions</h3><p>This case contributes to the limited data on disease course and treatment response of this rare disease process in a population that is under-represented in the literature. We note the importance of further studies to identify risk factors for refractory disease requiring early initiation of high-efficacy disease modifying treatment (DMT).</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100192"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X2300030X/pdfft?md5=b1b38b50fa7f97267d8101a19bd57fd0&pid=1-s2.0-S2667257X2300030X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136696887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of refractory MOG-IgG-associated disease with ofatumumab: A first case report 奥法单抗成功治疗难治性MOG-IgG相关疾病：一例报告

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-09-09 DOI: 10.1016/j.nerep.2023.100183

Hao Chen , Yu Zhou , Mengjie Zhang , WenJuan Gong , Yingxiong Xiong , Bo Wang , Yiyi Zhou , Jin Chen , Xiaomu Wu , Daojun Hong

{"title":"Successful treatment of refractory MOG-IgG-associated disease with ofatumumab: A first case report","authors":"Hao Chen , Yu Zhou , Mengjie Zhang , WenJuan Gong , Yingxiong Xiong , Bo Wang , Yiyi Zhou , Jin Chen , Xiaomu Wu , Daojun Hong","doi":"10.1016/j.nerep.2023.100183","DOIUrl":"https://doi.org/10.1016/j.nerep.2023.100183","url":null,"abstract":"<div><h3>Background</h3><p>Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified and recurrent inflammatory demyelinating disease of the central nervous system (CNS) in both adults and children. Although MOGAD acute attacks usually appear to be very responsive to high dose steroids and plasma exchange, the long-term side effects of steroids should be highlighted especially in children. Attack-prevention treatments also lack of class-I evidence and prospective randomized placebo-controlled trials are needed to better guide prevention treatment in refractory cases. Long-term immunosuppressive maintenance with mycophenolate mofetil, azathioprine or rituximab may not always effective in patients experienced recurrent demyelinating attacks.</p></div><div><h3>Case presentation</h3><p>We reported a rare case of 17-year-old MOGAD patient who experienced eleven relapses with azathioprine, mycophenolate mofetil and rituximab in five years, and finally effectively treated with ofatumumab (OFA), a novel fully humanized anti-CD20 mAb.</p></div><div><h3>Conclusions</h3><p>Timely and efficient treatment is crucial for better prognosis in refractory MOGAD. The fully humanized OFA may be an optimal choice if multiple therapeutic drugs fail to achieve remission. Further research on comparing OFA and RTX in MOG patient is needed.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"4 ","pages":"Article 100183"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50193927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regaining walking and restoring corticospinal tract excitability after neuromyelitis optica spectrum disorder: A case report 视神经脊髓炎后恢复行走和皮质脊髓束兴奋性1例

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-11-20 DOI: 10.1016/j.nerep.2023.100193

Hui-Ting Shih , Hui-Ting Goh , Seema Sikka , Rita Hamilton , Chad Swank

引用次数: 0

Acute pontine tumefactive multiple sclerosis 急性桥脑肿胀性多发性硬化

Neuroimmunology Reports Pub Date : 2023-12-01 Epub Date: 2023-08-11 DOI: 10.1016/j.nerep.2023.100179

Yalda Nikanpour , M. Toledano , W. Oliver Tobin

引用次数: 0